Synthetic Biologics is a biotechnology company developing product candidates for serious infections and diseases. The company is developing a biologic for preventing C. diff infection as well as a series of monoclonal antibodies (mAbs) for treating serious infectious diseases. In … Continue reading →

DURECT is a specialty pharmaceutical company focused on developing innovative drugs for pain and chronic diseases, with late-stage development programs including REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil. The company’s proprietary oral, transdermal and injectable depot delivery technologies facilitate new indications and … Continue reading →

Tengion is a leading clinical-stage regenerative medicine company focused on the development of its pioneering Organ Regeneration Platform. This platform is intended to harness the body’s intrinsic regenerative pathways to regenerate an array of native-like organs and tissues, with the … Continue reading →

Tekmira Pharmaceuticals is a biopharmaceutical company and a leader in developing RNA interference (RNAi) therapeutics. The company is focused on advancing novel RNAi therapeutics and supplying pharmaceutical partners with its leading lipid nanoparticle delivery technology. Based in Vancouver, B.C., Tekmira … Continue reading →

Nymox Pharmaceutical is focused on researching and developing novel drugs and diagnostic products for the aging population. NX-1207, the company’s lead drug candidate, is a proprietary treatment for enlarged prostate or benign prostatic hyperplasia (BPH) that is currently in Phase … Continue reading →

ADVENTRX Pharmaceuticals is a biopharmaceutical company engaged in the development of proprietary product candidates for treating various diseases and conditions. ANX-188, the company’s lead product candidate, is initially being developed as a treatment for complications arising from sickle cell disease … Continue reading →

ACADIA Pharmaceuticals is a biopharmaceutical company with its focus on innovative treatments addressing unmet medical needs in neurological and related central nervous system disorders. Pimavanserin, which is in Phase III clinical development as a potential first-in-class treatment for Parkinson’s disease … Continue reading →

ZIOPHARM Oncology is a biopharmaceutical company engaged in developing and commercializing new cancer therapies. The company’s clinical programs include palifosfamide, currently being studied in two Phase 3 clinical trials; Ad-RTS IL-12, currently being tested in a Phase 2 clinical study; … Continue reading →

Apricus Biosciences is a biopharmaceutical company engaged in developing and marketing innovative treatments to help large patient populations across numerous high-demand therapeutic classes, including male and female sexual health. With three approved products, the company has additionally developed a strong … Continue reading →

Affymax is a Palo Alto, Calif.-based biopharmaceutical company. The company’s focus is on discovering, developing and delivering innovative therapies to improve the lives of patients suffering with kidney disease and other serious, often life-threatening illnesses. OMONTYS, the company’s first marketed … Continue reading →